📣 VC round data is live. Check it out!

Onward Medical Valuation Multiples

Discover Onward Medical's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like RxSight, Pro-Dex, Huons Co, TriSalus Life Sciences and more.

Onward Medical Overview

About Onward Medical

Onward Medical NV is developing and commercializing therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company’s technology platforms are based on ONWARD ARC Therapy (ARC Therapy), targeted, programmed electrical stimulation of the spinal cord designed to restore movement, independence, and health in people with SCI.


Founded

2015

HQ

Netherlands

Employees

103

Website

onwd.com

Financials (LTM)

Revenue: $10M
EBITDA: ($56M)

EV

$155M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Onward Medical Financials

Onward Medical reported last 12-month revenue of $10M and negative EBITDA of ($56M).

In the same LTM period, Onward Medical generated ($56M) in EBITDA losses and had net loss of ($57M).

Revenue (LTM)


Onward Medical P&L

In the most recent fiscal year, Onward Medical reported revenue of $6M and EBITDA of ($44M).

Onward Medical is unprofitable as of last fiscal year, with gross margin of 54%, EBITDA margin of (738%), and net margin of (816%).

See analyst estimates for Onward Medical
LTMLast FY202320242025202620272028
Revenue$10M$6M$79K$267K$4M
Gross Profit-$3M-$241K$3M
Gross Margin-54%-90%73%
EBITDA($56M)($44M)($40M)($38M)($44M)
EBITDA Margin(557%)(738%)(49959%)(14354%)(1000%)
EBIT Margin(575%)(799%)(52151%)(15224%)(1082%)
Net Profit($57M)($49M)($42M)($42M)($49M)
Net Margin(571%)(816%)(53207%)(15600%)(1105%)

Financial data powered by Morningstar, Inc.

Onward Medical Stock Performance

Onward Medical has current market cap of $219M, and enterprise value of $155M.

Market Cap Evolution


Onward Medical's stock price is $3.15.

Onward Medical share price decreased by 0.1% in the last 30 days, and by 37.3% in the last year.

Onward Medical has an EPS (earnings per share) of $-0.70.

See more trading valuation data for Onward Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$155M$219M-0.1%-0.1%-19.7%-37.3%$-0.70

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Onward Medical Valuation Multiples

Onward Medical trades at 15.6x EV/Revenue multiple, and (2.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Onward Medical

EV / Revenue (LTM)


Onward Medical Financial Valuation Multiples

As of June 2, 2026, Onward Medical has market cap of $219M and EV of $155M.

Onward Medical has a P/E ratio of (3.8x).

LTMLast FY202320242025202620272028
EV/Revenue15.6x26.0xn/mn/m35.3x
EV/EBITDA(2.8x)(3.5x)(3.9x)(4.1x)(3.5x)
EV/EBIT(2.7x)(3.3x)(3.8x)(3.8x)(3.3x)
EV/Gross Profit-48.6x-n/m48.6x
P/E(3.8x)(4.5x)(5.2x)(5.3x)(4.5x)
EV/FCF(2.8x)(3.4x)(4.1x)(4.2x)(3.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Onward Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Onward Medical Margins & Growth Rates

Onward Medical grew revenue by 160% and EBITDA by 30% in the last fiscal year.

In the most recent fiscal year, Onward Medical reported gross margin of 54%, EBITDA margin of (738%), and net margin of (816%).

See estimated margins and future growth rates for Onward Medical

Onward Medical Margins

Last FY202420252026202720282029
Gross Margin54%90%73%-
EBITDA Margin(738%)(14354%)(1000%)(369%)
EBIT Margin(799%)(15224%)(1082%)(395%)
Net Margin(816%)(15600%)(1105%)(392%)
FCF Margin(769%)(13936%)(1045%)(433%)

Onward Medical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth160%237%1551%252%
Gross Profit Growth--1224%-
EBITDA Growth30%(3%)15%30%
EBIT Growth28%(2%)17%28%
Net Profit Growth25%(1%)17%25%
FCF Growth46%(2%)24%46%

Data powered by FactSet, Inc. and Morningstar, Inc.

Onward Medical Operational KPIs

Onward Medical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.

Onward Medical's Rule of 40 is (118%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Onward Medical's Rule of X is 260% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Onward Medical
LTMLast FY202320242025202620272028
Rule of 40(403%)(118%)---
Bessemer Rule of X(171%)260%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.5M---
S&M Expenses to Revenue-44%1637%545%60%
G&A Expenses to Revenue-147%7621%1934%199%
R&D Expenses to Revenue209%298%20354%5433%326%
Opex to Revenue-852%52251%15314%1155%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Onward Medical Competitors

Onward Medical competitors include RxSight, Pro-Dex, Huons Co, TriSalus Life Sciences, Utah Medical, Carvolix, Orchestra BioMed, Asterasys, Ilex Medical and Treace Medical Concepts.

Most Onward Medical public comparables operate across Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
RxSight0.1x0.1x(0.3x)(0.2x)
Pro-Dex3.3x2.9x15.8x-
Huons Co0.7x-5.2x-
TriSalus Life Sciences4.5x4.2x(12.3x)(13.6x)
Utah Medical3.2x-8.5x-
Carvolix51.7x368.0x(17.8x)(11.7x)
Orchestra BioMed4.5x7.7x(2.9x)(2.2x)
Asterasys7.7x6.4x23.1x18.6x

This data is available for Pro users. Sign up to see all Onward Medical competitors and their valuation data.

Start Free Trial

Onward Medical VC Funding History

Before going public, Onward Medical raised $62M in total equity funding, across 2 rounds.


Onward Medical Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-21Undisclosed stageEQT; GIMV; Inkef; Invest-NL; Olympic Investments; Wellington Partners$32M-Onward Medical is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. The company's primary therapeutic approach is ARC Therapy, which can be delivered through implantable (ARC IM) or external (ARC EX) systems designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury. The company's work builds on more than a decade of basic science and preclinical research conducted at leading neuroscience laboratories, and it has received three Breakthrough Device Designations from the FDA encompassing both ARC IM and ARC EX systems. Onward Medical's first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide. The company went public on Euronext on October 21, 2021, with an IPO price of EUR 12.75 per share. Financial data from subsequent periods shows the company has generated minimal revenue, with quarterly revenue figures in the low single digits (in millions of EUR) as of the most recent reported periods, and the company has remained unprofitable with significant operating losses.
Apr-16Series AEQT; GIMV; Inkef; Wellington Partners$30M--

Acquisitions by Onward Medical

Onward Medical has acquired 1 company to date.

Last acquisition by Onward Medical was on October 22nd 2019. Onward Medical acquired NeuroRecovery Technologies for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Onward Medical

NeuroRecovery Technologies
Description
NeuroRecovery Technologies is a medical device firm stemming from research at UCLA, Caltech, and University of Louisville that designs functional electrical stimulation systems for paralysis recovery. Its technology targets spinal cord injury patients with portable stimulators restoring hand and arm function through patterned nerve activation. FDA-cleared devices demonstrate gains in grasp strength during clinical use at rehab centers. Established in 2014 and based in Louisville, Kentucky, the company advances multi-limb applications.
HQ CountryUnited States
HQ City
Los Angeles, CA
Deal Date22 Oct 2019
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Onward Medical acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Onward Medical

When was Onward Medical founded?Onward Medical was founded in 2015.
Where is Onward Medical headquartered?Onward Medical is headquartered in Netherlands.
How many employees does Onward Medical have?As of today, Onward Medical has over 103 employees.
Who is the CEO of Onward Medical?Onward Medical's CEO is Dave Marver.
Is Onward Medical publicly listed?Yes, Onward Medical is a public company listed on Euronext Brussels.
What is the stock symbol of Onward Medical?Onward Medical trades under ONWD ticker.
When did Onward Medical go public?Onward Medical went public in 2021.
Who are competitors of Onward Medical?Onward Medical main competitors include RxSight, Pro-Dex, Huons Co, TriSalus Life Sciences, Utah Medical, Carvolix, Orchestra BioMed, Asterasys, Ilex Medical, Treace Medical Concepts.
What is the current market cap of Onward Medical?Onward Medical's current market cap is $219M.
What is the current revenue of Onward Medical?Onward Medical's last 12 months revenue is $10M.
What is the current revenue growth of Onward Medical?Onward Medical revenue growth (NTM/LTM) is 155%.
What is the current EV/Revenue multiple of Onward Medical?Current revenue multiple of Onward Medical is 15.6x.
Is Onward Medical profitable?No, Onward Medical is not profitable.
What is the current EBITDA of Onward Medical?Onward Medical has negative EBITDA and is not profitable.
What is Onward Medical's EBITDA margin?Onward Medical's last 12 months EBITDA margin is (557%).
What is the current EV/EBITDA multiple of Onward Medical?Current EBITDA multiple of Onward Medical is (2.8x).
What is the current FCF of Onward Medical?Onward Medical's last 12 months FCF is ($55M).
What is Onward Medical's FCF margin?Onward Medical's last 12 months FCF margin is (550%).
What is the current EV/FCF multiple of Onward Medical?Current FCF multiple of Onward Medical is (2.8x).
How many companies Onward Medical has acquired to date?As of June 2026, Onward Medical has acquired 1 company.
What was the largest acquisition by Onward Medical?None of the M&A deals Onward Medical has completed have disclosed valuations.
What companies Onward Medical acquired?Onward Medical acquired NeuroRecovery Technologies.
In how many companies Onward Medical has invested to date?Onward Medical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Onward Medical

Lists including Onward Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial